Sort   by:  
 Page size 
ProteomicsExploring the molecular mechanisms behind the potentiation of chemotherapy effects by durvalumab in lung adenocarcinoma cell lines
Immune checkpoint inhibitors are increasingly used in combination with chemotherapy for treatment of non-small cell lung cancer, yet the success of combination therapies is relatively limited. Thus, more detailed insight regarding the tumour molecular markers that may affect the responsiveness of pa...
ORGANISM(S): Homo sapiens (Human) 
2023-05-12 | PXD040761 | Pride
Chemosensitivity Proteomics Resistance Lung adenocarcinoma Pemetrexed Durvalumab Cisplatin 
GenomicsExpression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors
Expression data from durvalumab, oleclumab and combo-treated xenograft NSCLC tumors
PRJNA788281 | ENA
GenomicsNeoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
PRJNA1043632 | ENA
UnknownDurvalumab: First Global Approval.
Not available
S-EPMC5636860 | biostudies-literature
UnknownDurvalumab activity in previously treated patients who stopped durvalumab without disease progression.
Not available
S-EPMC7451272 | biostudies-literature
TranscriptomicsDurvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 platform trial 
Durvalumab with olaparib was one of the experimental regimens evaluated in I-SPY 2, a neoadjuvant platform trial for high risk, early stage breast cancer, and graduated in the HER2- and HR+HER2- signatures. We hypothesized that (pre-treatment) expression-based immune signatures may predict response ...
ORGANISM(S): Homo sapiens 
2021-06-10 | GSE173839 | GEO
UnknownDurvalumab: A Review in Extensive-Stage SCLC.
Not available
S-EPMC8648650 | biostudies-literature
UnknownA Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.
Not available
S-EPMC12685463 | biostudies-literature
UnknownDurvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Not available
S-EPMC10824389 | biostudies-literature
TranscriptomicsNeoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial
Randomized phase II trial patients with early-stage non-small cell lung cancer were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation. We report, based on transcriptome analyses of resected tumors...
ORGANISM(S): Homo sapiens 
2023-11-26 | GSE248378 | GEO
Sort   by:  
 Page size